2018 Executive Sponsors
2018 Associate Sponsors
2018 Supporting Sponsors
Supporting & Educational Partners
2018 Media Partners
WHAT TO EXPECT AT IMMUNO-ONCOLOGY 360° 2018
Designed by lead advisors Axel Hoos, MD, PhD, SVP, Oncology R&D, GlaxoSmithKline, and James Gulley, MD, PhD, Head, Immunotherapy Section, Director, Medical Oncology Service, Office of the Clinical Director, Center for Cancer Research, National Cancer Institute, more than 70 speakers cover the full spectrum of IO research and development, from translational and clinical to emerging technologies, business aspects, investor relations and trends in the field.
Day One of this year’s event starts with the Discovery & Preclinical Plenary Session, which includes presentations on NK Cell CARs; target discovery for CAR-Ts and TCRs; combination IDO1 and PD-1 inhibition in metastatic melanoma; early clinical data on dual targeting of PDL1 and TGF Beta and NKG2D-based CAR-T cell therapy for cancer. The Investor Relations in Immunotherapy Plenary Session begins with a keynote evaluating and forecasting the IO space given by Andrew Baum, MD, Head of Global Healthcare, Managing Director, Equity Research, Citi, then continues with a venture capitalist perspective on the IO landscape, and an investor roundtable on the role of IO within large pharma moderated by Axel Hoos. The Translational Science and Biomarkers Plenary Session concludes the day with sessions on: the development of immune agonist anitbodies; tumor mutation burden as an emerging biomarker; molecular markers for predicting response; predictive models for oncology; the MORPHEUS Novel CIT Platform to address multiple combinations; cancer vaccinations and biomarkers of response; using TC Clonality for detecting minimal residual disease; the use of imaging biomarkers for immunotherapy and emerging concepts for detecting minimal residual disease using liquid biopsies.
Day Two begins with the New Trends & Collaboration Plenary Session. Presentations include a BioCentury report on industry trends, a bulletin from Endpoint News, a progress update on the Biden Cancer Initiative, and information on immuno-oncology progress in China. The IO Emerging Technologies & Innovative Solutions Plenary Session showcases companies with technologies and solutions that will help IO stakeholders advance developments to provide treatment for cancer patients. The day ends with a choice between concurrent sessions. Track 1 features a continuation of the Translational Science and Biomarker Session which covers immune suppression in the tumor micro-environment; neoantigen approaches for biomarkers and biomarker strategies to guide rational combinations. Following this session in Track 1 is the Business Aspects Plenary Session, which covers a summary of IO deals; a large pharma perspective on IO licensing technology and finally a panel on talent management for IO. The second option is Track 2, the Clinical Operations for IO Trials Plenary Session, which features a specialized section on the building blocks of clinical trial design and operations led by Andy Lee, SVP and Head of Global Clinical Trial Operations for Merck; a panel on the operational challenges of combinations and a talk on operational independent reviews for IO clinical endpoints. The day concludes with the Operational Aspects for Immunotherapy Imaging Plenary Session which covers inspection readiness for imaging data; scientific and medical support for managing oncology trials; project management for imaging; large pharma panel on imaging operational aspects.
Day Three opens with the Clinical Aspects Plenary Session. Topics covered include: balancing benefit and toxicity from immunotherapeutics and how to make recommendations to patients; maintenance therapy in NSCLC; Keytruda in combination with chemo in NSCLC; learnings from Kymriah; Pembrolizumab as a broad spectrum anticancer therapy both as mono and combination therapy; and the differences in long term benefit between classes of checkpoint modulators. The summit concludes with the Trout Group Situation Room. The session includes fireside chats with IO CEOs, a presentation on the investor life-cycle and how to maneuver at each stage of financing from seed to public market; and a panel discussion on immuno-oncology CEOs checking the target.
Throughout the entire conference, there are numerous possibilities for networking, as well as dedicated times for one-on-one partnering meetings. All breaks will be held in the exhibition hall where attendees can meet with organizations that provide tools and resources which may be helpful in supporting and advancing their IO pipelines. There will also be small, numbered tables during the conference, which attendees can reserve for one-on-one meetings in advance or onsite via the Trout Group partnering software tool. We invite you to join us at the end of Day Two in the exhibition hall for a Networking Reception.
We look forward to meeting you February.
“Now in its fourth year, IO360° continues to help the immuno-oncology community stay at the forefront of the most relevant research and developments from key industry leaders, who have their fingers on the pulse of cancer immunotherapy.” – Kate Woda, IO360° Director